section,entity_id,entity_name,entity_name_en,entity_type,category,attribute_path,value,evidence_source
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,alternate_names,自身免疫性多内分泌病I型; APECED (Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy); 慢性皮肤黏膜念珠菌病-多内分泌病-外胚层发育不良综合征,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.genetic_basis.gene,AIRE (Autoimmune Regulator),ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.genetic_basis.chromosome,21q22.3,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.genetic_basis.inheritance,常染色体隐性遗传,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.genetic_basis.protein_function,转录调节因子，调控胸腺髓质上皮细胞中自身抗原表达,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.genetic_basis.mutations.common_types,无义突变; 剪接位点突变; 框移突变; 错义突变,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.genetic_basis.mutations.functional_impact,AIRE蛋白功能缺失导致中枢免疫耐受破坏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.immune_mechanism.central_tolerance_defect,胸腺阴性选择缺陷,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.immune_mechanism.autoantigen_presentation,组织特异性抗原胸腺内表达减少,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.immune_mechanism.t_cell_selection,自反应T细胞逃逸阴性选择,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.immune_mechanism.autoantibody_production,多器官特异性自身抗体产生,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.molecular_pathways.transcriptional_regulation,AIRE调控的转录组异常,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.molecular_pathways.promiscuous_gene_expression,胸腺内异位基因表达受损,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,pathophysiology.molecular_pathways.immune_tolerance,自身免疫耐受机制破坏,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.candidiasis.description,慢性皮肤黏膜念珠菌感染,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.candidiasis.onset,通常首发症状（2-5岁）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.candidiasis.sites,口腔（鹅口疮）; 食管; 皮肤; 指甲; 生殖器,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.candidiasis.characteristics,反复发作，难以根治,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.candidiasis.complications,食管狭窄，口腔癌风险,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.hypoparathyroidism.prevalence,89-96%患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.hypoparathyroidism.onset_age,5-10岁,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.hypoparathyroidism.symptoms,手足搐搦; 癫痫; 喉痉挛; 感觉异常; 肌肉痛性痉挛,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.hypoparathyroidism.biochemical,低钙血症，高磷血症，PTH降低,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.hypoparathyroidism.complications,白内障; 基底节钙化; 智力发育障碍,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.addison_disease.prevalence,72-100%患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.addison_disease.onset_age,青少年期,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.addison_disease.manifestations,色素沉着; 乏力，体重下降; 恶心呕吐; 低血压; 电解质紊乱,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.classic_triad.addison_disease.crisis_risk,肾上腺危象风险高,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.additional_endocrine_features.gonadal_dysfunction.prevalence,60%患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.additional_endocrine_features.gonadal_dysfunction.manifestations,原发性性腺功能减退; 青春期发育延迟; 不孕不育; 闭经,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.additional_endocrine_features.diabetes_mellitus.type,1型糖尿病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.additional_endocrine_features.diabetes_mellitus.prevalence,12-18%患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.additional_endocrine_features.diabetes_mellitus.onset,通常青少年期,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.additional_endocrine_features.thyroid_disease.hypothyroidism,自身免疫性甲状腺炎,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.additional_endocrine_features.thyroid_disease.prevalence,4-10%患者,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.additional_endocrine_features.growth_hormone_deficiency.prevalence,罕见,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.additional_endocrine_features.growth_hormone_deficiency.manifestations,生长发育迟缓,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.non_endocrine_features.ectodermal_dystrophy.dental_abnormalities,牙釉质发育不良; 龋齿易感; 牙齿缺失,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.non_endocrine_features.ectodermal_dystrophy.nail_dystrophy,甲板增厚，甲沟炎,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.non_endocrine_features.ectodermal_dystrophy.alopecia,斑秃或弥漫性脱发,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.non_endocrine_features.gastrointestinal.autoimmune_hepatitis,慢性活动性肝炎,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.non_endocrine_features.gastrointestinal.pernicious_anemia,恶性贫血（B12缺乏）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.non_endocrine_features.gastrointestinal.malabsorption,肠道吸收不良,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.non_endocrine_features.dermatologic.vitiligo,白癜风,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.non_endocrine_features.dermatologic.autoimmune_skin_conditions,各种自身免疫性皮肤病,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.non_endocrine_features.ocular.keratoconjunctivitis,角膜结膜炎,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.non_endocrine_features.ocular.uveitis,葡萄膜炎,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.clinical_criteria.major_criteria,慢性皮肤黏膜念珠菌感染; 甲状旁腺功能减退; 肾上腺功能不全,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.clinical_criteria.minor_criteria,性腺功能减退; 1型糖尿病; 自身免疫性甲状腺炎; 恶性贫血; 慢性活动性肝炎; 斑秃; 白癜风,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.clinical_criteria.diagnostic_threshold,≥2个主要标准 或 1个主要+≥2个次要标准,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.autoantibodies.21_hydroxylase,抗21-羟化酶抗体（肾上腺）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.autoantibodies.side_chain_cleavage,抗胆固醇侧链裂解酶抗体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.autoantibodies.17_hydroxylase,抗17α-羟化酶抗体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.autoantibodies.calcium_sensing_receptor,抗钙敏感受体抗体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.autoantibodies.interferon_omega,抗干扰素ω抗体（高特异性）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.autoantibodies.interferon_alpha,抗干扰素α抗体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.autoantibodies.il22,抗IL-22抗体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.autoantibodies.il17,抗IL-17抗体,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.hormone_assessment.adrenal,皮质醇，ACTH，醛固酮，肾素,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.hormone_assessment.parathyroid,PTH，钙，磷，维生素D,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.hormone_assessment.gonadal,LH，FSH，睾酮/雌二醇,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.hormone_assessment.thyroid,TSH，T4，T3，抗TPO,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.hormone_assessment.pancreatic,胰岛素，C肽，HbA1c,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.immunological.candida_immunity,念珠菌特异性T细胞反应,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.immunological.cytokine_profiles,Th17/Th1细胞因子,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.laboratory_investigations.immunological.complement,补体系统评估,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.genetic_testing.aire_sequencing,AIRE基因全外显子测序,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.genetic_testing.family_screening,家系成员基因筛查,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.genetic_testing.prenatal_diagnosis,产前基因诊断（家族史阳性）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.imaging.adrenal_ct,肾上腺CT（萎缩征象）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.imaging.thyroid_ultrasound,甲状腺超声,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.imaging.bone_density,骨密度检测,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,diagnosis.imaging.brain_ct,颅脑CT（基底节钙化）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.hormone_replacement.adrenal.hydrocortisone,15-25mg/day分次服用,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.hormone_replacement.adrenal.fludrocortisone,0.05-0.2mg/day（盐皮质激素）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.hormone_replacement.adrenal.emergency_management,应激状态下剂量调整,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.hormone_replacement.parathyroid.calcitriol,0.25-2μg/day,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.hormone_replacement.parathyroid.calcium_carbonate,1-3g/day元素钙,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.hormone_replacement.parathyroid.monitoring,定期监测血钙、尿钙,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.hormone_replacement.gonadal.testosterone,男性睾酮补充治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.hormone_replacement.gonadal.estrogen_progesterone,女性雌孕激素替代,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.hormone_replacement.thyroid.levothyroxine,甲状腺功能减退时补充,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.hormone_replacement.diabetes.insulin,1型糖尿病胰岛素治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.antimycotic_therapy.systemic_antifungals.fluconazole,100-400mg/day长期维持,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.antimycotic_therapy.systemic_antifungals.itraconazole,100-200mg/day,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.antimycotic_therapy.systemic_antifungals.posaconazole,难治性感染时选择,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.antimycotic_therapy.topical_treatment.nystatin,口腔念珠菌感染,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.antimycotic_therapy.topical_treatment.clotrimazole,皮肤念珠菌感染,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.antimycotic_therapy.prophylaxis,长期抗真菌预防治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.immunomodulatory_therapy.investigational,免疫抑制剂（环孢素A）; 生物制剂（抗IL-17）; 造血干细胞移植,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.immunomodulatory_therapy.supportive_care,营养支持，感染预防,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.monitoring_strategy.hormone_levels,定期激素水平监测,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.monitoring_strategy.autoantibody_screening,新发自身免疫疾病筛查,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.monitoring_strategy.infection_surveillance,感染并发症监测,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.monitoring_strategy.malignancy_screening,口腔癌筛查（念珠菌感染区域）,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,prognosis.life_expectancy,激素替代治疗下预后良好,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,prognosis.quality_of_life,需要终生多种激素替代治疗,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,prognosis.complications,肾上腺危象; 低钙血症性癫痫; 感染相关并发症; 恶性肿瘤风险增加,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,prognosis.genetic_counseling,家族遗传咨询重要,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,research_insights.aire_function,AIRE蛋白免疫耐受机制研究,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,research_insights.therapeutic_targets,新型免疫调节治疗靶点,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,research_insights.gene_therapy,基因治疗策略探索,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,research_insights.biomarkers,疾病活动度生物标志物,ADA Standards of Medical Care in Diabetes 2025; American Thyroid Association Guidelines 2025; Endocrine Society Adrenal Guidelines 2024; Endocrine Society Pituitary Guidelines 2024; AHA/ACC Hypertension Guidelines 2025; ACC/AHA Dyslipidemia Guidelines 2025; Endocrine Society Growth Hormone Guidelines 2024; ATA Thyroid Nodules Management Guidelines 2024; Primary Aldosteronism Guidelines 2024; Pheochromocytoma and Paraganglioma Guidelines 2024; Androgen Excess and PCOS Society Guidelines 2023; International Society of Endocrinology Clinical Practice Guidelines; American Urological Association Male Hypogonadism Guidelines 2024; North American Menopause Society Position Statement 2024
